State of the Science Summit on Multiple Myeloma and Myeloproliferative Neoplasms | Conference

Dr. Wolf Discusses High-Risk Multiple Myeloma

May 2nd 2018

Jeffrey Wolf, MD, clinical professor, Department of Medicine, director, Myeloma Program, University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses high-risk multiple myeloma.

Dr. Rosenzweig Discusses the Standard of Care in Amyloidosis

May 2nd 2018

Michael Rosenzweig, MD, assistant professor in the Department of Hematology and Hematopoietic Cell Transplantation at City of Hope, discusses the standard of care for the treatment of patients with amyloidosis.

Expert Details Developments in MPN Paradigm

May 1st 2018

David S. Snyder, MD, details mutations and discusses investigational treatments within the field of myeloproliferative neoplasms.

Novel Approaches Emerge in AL Amyloidosis

April 27th 2018

Michael Rosenzweig, MD, discusses emerging treatment options for patients with immunoglobulin light chain amyloidosis such as daratumumab and NEOD001.

Dr. Rosenzweig Discusses Emerging Agents in Amyloidosis

April 27th 2018

Michael Rosenzweig, MD, assistant professor in the department of Hematology and Hematopoietic Cell Transplantation at City of Hope, discusses emerging agents in the treatment of patients with amyloidosis.

Expert Covers Burgeoning Role of CAR T-Cell Therapy in Myeloma

April 26th 2018

Maung Myo Htut, MD, discusses the use of CAR T-cell therapy in multiple myeloma and the potential infusion of immunotherapy into treatment.

Options Continue to Emerge for Transplant-Ineligible Multiple Myeloma

April 26th 2018

Nitya Nathwani, MD, highlights current treatment options for transplant-ineligible multiple myeloma, as well as combinations on the horizon.

Dr. Snyder on Ruxolitinib in Patients With Myelofibrosis

April 25th 2018

David S. Snyder, MD, associate chair and professor, Department of Hematology and Hematopoietic Cell Transplantation, City of Hope, discusses the use of ruxolitinib (Jakafi) in myelofibrosis.

Dr. Htut on CAR T-Cell Therapy in Patients With Multiple Myeloma

April 24th 2018

Maung Myo Htut, MD, assistant clinical professor of hematology and hematopoietic cell transplantation, City of Hope, discusses the use of chimeric antigen receptor (CAR) T-cell therapy in patients with multiple myeloma.

Dr. Nathwani on the Standard of Care in Patients With Newly Diagnosed Multiple Myeloma

April 20th 2018

Nitya Nathwani, MD, assistant clinical professor, Hematology and Hematopoietic Cell Transplantation, City of Hope, discusses the standard of care in patients with newly diagnosed multiple myeloma.